Rifaximin pharmacology and clinical implications

Bibliography

• Marchi E, Montecchi L, Venturini AP, et al. 4-Deoxypyrido[1′,2′:1,2]imidazo[5,4-c]rifamycin SV derivatives. A new series of semisynthetic rifamycins with high antibacterial activity and low gastroenteric absorption. J Med Chem 1985;28:960-3
   PubMed Web of Science ®Google Scholar
• Rifaximin label approved on 05/25/2004. Available from: http://www.fda.gov/cder/foi/label/2004/ 21361_xifaxan_lbl.pdf
   Google Scholar
• Scarpignato C, Pelosini I. Rifaximin, a poorly absorbed antibiotic: pharmacology and clinical potential. Chemotherapy 2005;51(Suppl 1):36-66
   PubMed Web of Science ®Google Scholar
• Robins GW, Wellington K. Rifaximin. A review of its use in the management of traveller's diarrhoea. Drugs 2005;65:1697-713
   PubMed Web of Science ®Google Scholar
• Hoover WW, Gerlach EH, Hoban DJ, et al. Antimicrobial activity and spectrum of rifaximin, a new topical rifamycin derivative. Diagn Microbiol Infect Dis 1993;16:111-8
   PubMed Web of Science ®Google Scholar
• Lal R, Lal S. Recent trends in rifamycin research. Bioessays 1994;16:211-6
   PubMed Web of Science ®Google Scholar
• Holton J, Vaira D, Menegatti M, Barbara L. The susceptibility of Helicobacter pylori to the rifamycin, rifaximin. J Antimicrob Chemother 1995;35:545-9
   PubMed Web of Science ®Google Scholar
• Sierra JM, Ruiz J, Navia MM, et al. In vitro activity of rifaximin against enteropathogens producing travelers′ diarrhea. Antimicrob Agents Chemother 2001;45:643-4
   PubMed Web of Science ®Google Scholar
• Jiang ZD, Dupont HL. Rifaximin: in vitro and in vivo antibacterial activity–a review. Chemotherapy 2005;51(Suppl 1):67-72
   PubMed Web of Science ®Google Scholar
• Venturini AP. Pharmacokinetics of L/105, a new rifamycin, in rats and dogs, after oral administration. Chemotherapy 1983;29:1-3
   PubMed Web of Science ®Google Scholar
• Descombe JJ, Dubourg D, Picard M, Palazzini E. Pharmacokinetic study of rifaximin after oral administration in healthy volunteers. Int J Clin Pharmacol Res 1994;14:51-6
   PubMedGoogle Scholar
• Taylor DN, McKenzie R, Durbin A, et al. Rifaximin, a nonabsorbed oral antibiotic, prevents shigellosis after experimental challenge. Clin Infect Dis 2006;42(9):1283-8
   PubMed Web of Science ®Google Scholar
• Gerard L, Garey KW, DuPont HL. Rifaximin: a nonabsorbable rifamycin antibiotic for use in nonsystemic gastrointestinal infections. Expert Rev Anti Infect Ther 2005;3:201-11
   PubMedGoogle Scholar
• Ito S, Lee A. Drug excretion into breast milk – overview. Adv Drug Deliv Rev 2003;55:617-27
   PubMed Web of Science ®Google Scholar
• Pentikis HS, Connolly M, Trapnell CB, et al. The effect of multiple-dose, oral rifaximin on the pharmacokinetics of intravenous and oral midazolam in healthy volunteers. Pharmacotherapy 2007;27(10):1361-9
   PubMed Web of Science ®Google Scholar
• King A, Marshall O, Connolly M, et al. The effect of rifaximin on the pharmacokinetics of a single dose of ethinyl estardiol and norgestimate in healthy female volunteers. Clin Pharmacol Ther 2004;75:P96
   Google Scholar
• Borelli G, Bertoli D. Acute, subacute, chronic toxicity and mutagenicity studies of rifaximin (L/105) in rats. Chemioterapia 1986;5:263-7
   PubMedGoogle Scholar
• Ericsson CD. Travellers′ diarrhoea. Int J Antimicrob Agents 2003;21:116-24
   PubMed Web of Science ®Google Scholar
• Taylor DN. Poorly absorbed antibiotics for the treatment of traveler's diarrhea. Clin Infect Dis 2005;41(Suppl 8):S564-70
   PubMed Web of Science ®Google Scholar
• DuPont HL, Jiang ZD, Ericsson CD, et al. Rifaximin versus ciprofloxacin for the treatment of traveler's diarrhea: a randomized, double-blind clinical trial. Clin Infect Dis 2001;33(11):1807-15
   PubMed Web of Science ®Google Scholar
• Taylor DN, Bourgeois AL, Ericsson CD, et al. A randomized, double-blind, multicenter study of rifaximin compared with placebo and with ciprofloxacin in the treatment of travelers′ diarrhea. Am J Trop Med Hyg 2006;74(6):1060-6
   PubMed Web of Science ®Google Scholar
• Ericsson CD. Safety and tolerability of the antibacterial rifaximin in the treatment of travellers′ diarrhoea. Drug Saf 2006;29(3):201-7
   PubMed Web of Science ®Google Scholar
• Du Pont HL. Travellers′ diarrhoea: contemporary approaches to therapy and prevention. Drugs 2006;66(3):303-14
   PubMed Web of Science ®Google Scholar
• DuPont HL. Systematic review: prevention of travellers′ diarrhoea. Aliment Pharmacol Ther 2008;27(9):741-51
   PubMed Web of Science ®Google Scholar
• Als-Nielsen B, Gluud LL, Gluud C. Non-absorbable disaccharides for hepatic encephalopathy: systematic review of randomised trials. BMJ 2004;328:1046
   PubMed Web of Science ®Google Scholar
• Jiang Q, Jiang XH, Zheng MH, et al. Rifaximin versus nonabsorbable disaccharides in the management of hepatic encephalopathy: a meta-analysis. Eur J Gastoenterol Hepatol 2008;20(11):1064-70
   PubMed Web of Science ®Google Scholar
• Lawrence KL, Klee JR. Rifaximin for the treatment of hepatic encephalopathy. Pharmacotherapy 2008;28(8):1019-32
   PubMed Web of Science ®Google Scholar
• Maclayton DO, Eaton-Maxwell A. Rifaximin for treatment of hepatic encephalopathy. Ann Pharmacother 2008
   PubMedGoogle Scholar
• Quiglay EM, Quera R. Small intestinal bacterial overgrowth: roles of antibiotics, prebiotics, and probiotics. Gastroenterology 2006;130(2 Suppl 1):78-90
   Google Scholar
• Singh VV, Toskes PP. Small bowel bacterial overgrowth: presentation, diagnosis, and treatment. Curr Treat Options Gastroenterol 2004;7:19-28
   PubMedGoogle Scholar
• Lupascu A, Gabrielli M, Lauritano EC, et al. Hydrogen glucose breath test to detect small intestinal bacterial overgrowth: a prevalence case-control study in irritable bowel syndrome. Aliment Pharmacol Ther 2005;22:1157-60
   PubMed Web of Science ®Google Scholar
• Pimentel M, Chow EJ, Lin HC. Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome. Am J Gastroenterol 2000;95:3503-6
   PubMed Web of Science ®Google Scholar
• Di Stefano M, Malservisi S, Veneto G, et al. Rifaximin versus chlortetracycline in the short term treatment of small intestinal bacterialovergrowth. Aliment Pharmacol Ther 2000;14:551-6
   PubMed Web of Science ®Google Scholar
• Lauritano EC, Gabrielli M, Lupascu A, et al. Rifaximin dose-finding study for the treatment of small intestinal bacterial overgrowth. Aliment Pharmacol Ther 2005;22(1):31-5
   PubMed Web of Science ®Google Scholar
• Scarpellini E, Gabrielli M, Lauritano CE, et al. High dosage rifaximin for the treatment of small intestinal bacterial overgrowth. Aliment Pharmacol Ther 2007;25(7):781-6
   PubMed Web of Science ®Google Scholar
• Lauritano EC, Gabrielli M, Scarpellini E, et al. Antibiotic therapy in small intestinal bacterial overgrowth: rifaximin versus metronidazole. Eur Rev Med Pharmacol Sci 2009; In press
   Google Scholar
• Lauritano EC, Gabrielli M, Scarpellini E, et al. Small intestinal bacterial overgrowth recurrence after antibiotic therapy. Am J Gastroenterol 2008;103(8):2031-5
   PubMed Web of Science ®Google Scholar
• Parodi A, Paolino S, Greco A, et al. Small intestinal bacterial overgrowth in rosacea: clinical effectiveness of its eradication. Clin Gastroenterol Hepatol 2008;6(7):759-64
   PubMed Web of Science ®Google Scholar
• Domsic R, Fasanella K, Bielefeldt K. Gastrointestinal manifestations of systemic sclerosis. Dig Dis Sci 2008;53(5):1163-74
   PubMed Web of Science ®Google Scholar
• Parodi A, Sessarego M, Greco A, et al. Small intestinal bacterial overgrowth in patients suffering from scleroderma: clinical effectiveness of its eradication. Am J Gastroenterol 2008;103(5):1257-62
   PubMed Web of Science ®Google Scholar
• Resmini E, Parodi A, Savarino V, et al. Evidence of prolonged orocecal transit time and small intestinal bacterial overgrowth in acromegalic patients. J Clin End Met 2007;92(6):2119-24
   PubMed Web of Science ®Google Scholar
• Sartor RB. Enteric microflora in IBD: pathogens or commensal? Inflamm Bowel Dis 1997;3:230-5
   PubMed Web of Science ®Google Scholar
• Duchman R, Kaiser I, Hermann E, et al. Tolerance exists towards resident intestinal flora but is broken in active inflammatory bowel disease (IBD). Clin Exp Immunol 1995;102:448-55
   PubMed Web of Science ®Google Scholar
• Rutgeerts P, Goboes K, Peeters M, et al. Effect of fecal stream diversion on recurrence of Crohn's disease in the neoterminal ileum. Lancet 1991;338:771-4
   PubMed Web of Science ®Google Scholar
• Swidsinsky A, Ladhoff A, Pernthaler A, et al. Mucosal flora in inflammatory bowel disease. Gastroenterology 2002;122:44-54
   PubMed Web of Science ®Google Scholar
• Sartor RB. Targeting enteric bacteria in treatment of inflammatory bowel diseases: why, how, and when? Curr Opin Gastroenterol 2003;19:358-65
   PubMed Web of Science ®Google Scholar
• Gionchetti P, Rizzello F, Venturi A, et al. Rifaximin in patients with moderate or severe ulcerative colitis refractory to steroid treatment: a double-blind placebo controlled trial. Dig Dis Sci 1999;44:1220-1
   PubMed Web of Science ®Google Scholar
• Guslandi M, Perone MC, Testoni PA. Rifaximin for active ulcerative colitis. Inflamm Bowel Dis 2006;12(4):235
   Google Scholar
• Campieri M, Rizzello F, Venturi A, et al. Combination of antibiotic and probiotic treatment is efficacious in prophylaxis of post-operative recurrence of Crohn's disease. A randomized controlled study vs mesalazine. Gastroenterology 2000;118(Suppl 1):A781
   Web of Science ®Google Scholar
• Shafran I, Johnson LK. An open-label evaluation of rifaximin in the treatment of active Crohn's disease. Curr Med Res Opin 2005;21:1165-9
   PubMed Web of Science ®Google Scholar
• Prantera C, Lochs H, Campieri M, et al. Antibiotic tratment of Crohn's disease: results of a multicentre double-blind, randomized, placebo-controlled trial with rifaximin. Aliment Pharmacol Ther 2006;23(8):1117-25
   PubMed Web of Science ®Google Scholar
• Gionchetti P, Rizzello F, Morselli C, et al. Management of inflammatory bowel disease: Does rifaximin offer any promise? Chemoterapy 2005;51(Suppl 1):96-102
   PubMed Web of Science ®Google Scholar
• Guslandi M. Antibiotic for inflammatory bowel disease: do they work? Eur J Gastroenterol Hepatol 2005;17:145-7
   PubMed Web of Science ®Google Scholar
• Gionchetti P, Rizzello F, Lammers KM, et al. Antimicrobials in the management of inflammatory bowel disease. Digestion 2006;73(Suppl 1):77-85
   PubMed Web of Science ®Google Scholar
• Parks TG. Natural history of diverticular disease of the colon. Clin Gastroenterol 1975;4:53-69
   PubMedGoogle Scholar
• Stollman N, Raskin JB. Diverticular disease of the colon. Lancet 2004;363:631-9
   PubMed Web of Science ®Google Scholar
• Nakada I, Ubukata H, Goto Y. Diverticular disease of the colon at a regional general hospital in Japan. Dis Colon Rectum 1995;38:755-9
   PubMed Web of Science ®Google Scholar
• Petruzziello L, Iacopini F, Bulajic M, et al. Review article: uncomplicated diverticular disease of the colon. Aliment Pharmacol Ther 2006;23:1379-91
   PubMed Web of Science ®Google Scholar
• Latella G, Pimpo MT, Sottili S, et al. Rifaximin improves symptoms of acquired uncomplicated diverticular disease of the colon. Int J Colorectal Dis 2003;18:55-62
   PubMed Web of Science ®Google Scholar
• D'Incà R, Pomerri F, Vettorato MG, et al. Interaction between rifaximin and dietary fibre in patients with diverticular disease. Aliment Pharmacol Ther 2007;25:771-9
   PubMed Web of Science ®Google Scholar
• Colecchia A, Vestito A, Pasqui F, et al. Efficacy of long term cyclic administration of the poorly absorbed antibiotic Rifaximin in symptomatic, uncomplicated colonic diverticular disease. World J Gastroenterol 2007;13:264-9
   PubMed Web of Science ®Google Scholar